You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 16, 2025

Claims for Patent: 11,618,748


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 11,618,748
Title:Dual mechanism inhibitors for the treatment of disease
Abstract:Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.
Inventor(s):Mitchell A. deLong, Jill Marie Sturdivant, Susan M. Royalty
Assignee: Alcon Inc
Application Number:US17/243,272
Patent Claims: 1. A method of reducing intraocular pressure, comprising administration of a composition comprising a Rho kinase inhibitor and a pharmaceutically acceptable carrier to a subject in need thereof, wherein the administration is daily administration, weekly administration, or monthly administration, wherein the Rho kinase inhibitor is: or a pharmaceutically acceptable salt thereof, wherein R1, R2, and R3 are independently hydrogen, C1-C4 alkyl, aryl, C1-C4 alkyl aryl, C1-C4 alkyl heteroaryl, C1-C4 alkyl heterocyclyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 carbonyl, C1-C4 carbonylamino, C1-C4 alkoxy, C1-C4 sulfonyl, C1-C4 sulfonylamino, C1-C4 thioalkyl, C1-C4 carboxyl, or form a ring with each other or with A; A is C1-C4 alkyl, C1-C4 alkyl aryl, C1-C4 alkyl heteroaryl, or forms a ring structure with R1, R2 or R3; B is hydrogen, an aryl group, a heteroaryl group, a cycloalkyl group, a heterocycloalkyl group, C1-C22 alkyl, C1-C22 alkyl aryl, C1-C22 alkyl heteroaryl, C2-C22 alkenyl, C2-C22 alkynyl, C1-C22 carbonyl, C1-C22 carbonylamino, C1-C22 alkoxy, C1-C22 sulfonyl, C1-C22 sulfonylamino, C1-C22 thioalkyl, or C1-C22 carboxyl; X1, X2, and X3 are, independently, hydrogen, hydroxyl, halogen, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, amino, aminocarbonyl, nitro, cyano, C1-C4 carbonyl, C1-C4 carbonylamino, C1-C4 alkoxy, C1-C4 sulfonyl, C1-C4 sulfonylamino, C1-C4 thioalkyl, or C1-C4 carboxyl; the double circle indicates an aromatic or heteroaromatic ring; and each Z is independently a bond, C1-C4 alkyl, heteroalkyl, or an O atom.

2. The method of claim 1, wherein the administration is ocular administration.

3. The method of claim 1, wherein the amount of the compound administered is about 0.001 to about 100 mg/kg subject body weight.

4. The method of claim 1, wherein the administration is once daily, twice per day, or 4 times per day.

5. The method of claim 2, wherein the administration is once daily, twice per day, or 4 times per day.

6. The method of claim 3, wherein the administration is once daily, twice per day, or 4 times per day.

7. The method of claim 1, wherein the administration is once weekly or twice weekly.

8. The method of claim 2, wherein the administration is once weekly or twice weekly.

9. The method of claim 3, wherein the administration is once weekly or twice weekly.

10. The method of claim 1, wherein the administration is once a month.

11. The method of claim 2, wherein the administration is once a month.

12. The method of claim 3, wherein the administration is once a month.

13. A method of treating glaucoma or ocular hypertension, comprising administration of a composition comprising a Rho kinase inhibitor and a pharmaceutically acceptable carrier to a subject in need thereof, wherein the administration is daily administration, weekly administration, or monthly administration, wherein the Rho kinase inhibitor is: or a pharmaceutically acceptable salt thereof.

14. The method of claim 13, wherein the administration is ocular administration.

15. The method of claim 13, wherein the amount of the compound administered is about 0.001 to about 100 mg/kg subject body weight.

16. The method of claim 13, wherein the administration is once daily, twice per day, or 4 times per day.

17. The method of claim 14, wherein the administration is once daily, twice per day, or 4 times per day.

18. The method of claim 15, wherein the administration is once daily, twice per day, or 4 times per day.

19. The method of claim 13, wherein the administration is once weekly or twice weekly.

20. The method of claim 14, wherein the administration is once weekly or twice weekly.

21. The method of claim 15, wherein the administration is once weekly or twice weekly.

22. The method of claim 13, wherein the administration is once a month.

23. The method of claim 14, wherein the administration is once a month.

24. The method of claim 15, wherein the administration is once a month.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.